[Form 4] HEALTHSTREAM INC Insider Trading Activity
Rhea-AI Filing Summary
Trisha L. Coady, Executive Vice President of HealthStream, Inc. (HSTM), reported a grant of 2,586 restricted share units (RSUs) on 09/24/2025. Each RSU converts into one share of common stock upon vesting. The RSUs carry a four-year service-based vesting schedule: 15% vest on 09/24/2026, 20% on 09/24/2027, 30% on 09/24/2028, and 35% on 09/24/2029. The reported RSUs have an exercise/issuance price of $0 and are listed as directly beneficially owned following the transaction. The filing also shows a non-derivative entry referencing 29,932 common shares with a disposition code indicated.
Positive
- 2,586 RSUs granted to Executive Vice President Trisha L. Coady, which align compensation with multi-year service and retention
- Clear vesting schedule disclosed: 15% (09/24/2026), 20% (09/24/2027), 30% (09/24/2028), 35% (09/24/2029)
Negative
- Disposition of 29,932 common shares is shown on the non-derivative section, indicating a reduction in reported holdings
Insights
TL;DR: Grant of service-based RSUs to an executive aligns pay with retention; filing also records a disposition of common shares.
The 2,586 RSU grant is standard executive compensation tied to continued service, using a four-year schedule that front-loads early retention with a 15% first-year vesting and back-loads the largest tranche (35%) in year four.
This Form 4 also records a non-derivative entry showing 29,932 common shares with a disposition marker, which is an explicit change in share ownership reported by the insider. The disclosure is procedural and consistent with routine equity compensation and insider reporting requirements.
TL;DR: Small RSU grant and an indicated disposition are routine insider transactions; no financial metrics provided to assess material impact.
The awarded 2,586 RSUs convert to the same number of shares upon vesting and carry no cash exercise cost, indicating restricted stock units rather than options. The transaction date is 09/24/2025 and ownership post-transaction is reported as 2,586 RSUs directly owned. The Form 4 does not include transaction prices for the non-derivative line beyond the disposition marker for 29,932 shares, so valuation impact cannot be determined from this filing alone.